Oxaliplatin

Name: Oxaliplatin
Brand: Selleck Chemicals
SKU: S1224
Rating: 5 (100 reviews)

For research use only.

Catalog No.S1224 Synonyms: L-OHP

100 publications

CAS No. 61825-94-3

Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Selleck's Oxaliplatin has been cited by 100 publications

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cancer Cell, 2018, 33(6):1094-1110

PubMed: 29805078 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Nat Microbiol, 2021, 10.1038/s41564-020-00831-6

PubMed: 33432149 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):10

PubMed: 33407548 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

ACS Nano, 2020, 28;14(4):5075-5089

PubMed: 32283007 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4815-4827

PubMed: 32907836 ( click the link to review the publication )

J Control Release, 2020, 319:213-221

PubMed: 31899270 ( click the link to review the publication )

J Hematol Oncol, 2020, 1;13(1):40

PubMed: 32357935 ( click the link to review the publication )

Oncogene, 2020, 39(5):987-1003

PubMed: 31591478 ( click the link to review the publication )

Cancer Lett, 2020, 28;476:67-74

PubMed: 32061752 ( click the link to review the publication )

Cancer Lett, 2020, 473:74-89

PubMed: 31904482 ( click the link to review the publication )

Acta Biomater, 2020, S1742-7061(20)30751-0

PubMed: 33388439 ( click the link to review the publication )

Cancers (Basel), 2020, 30;12(5):E1118

PubMed: 32365785 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2580

PubMed: 32927726 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):822

PubMed: 33009373 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Cells, 2020, 9(9)E2110

PubMed: 32948057 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-0133

PubMed: 32029633 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )
Cell Discov, 2020, 21;6:21

PubMed: 32351703 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:473

PubMed: 33005106 ( click the link to review the publication )

Front Pharmacol, 2020, 11:597520

PubMed: 33343368 ( click the link to review the publication )

Front Pharmacol, 2020, 10;11:252

PubMed: 32210825 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-020-04187-w

PubMed: 33169187 ( click the link to review the publication )

Photochem Photobiol, 2020, 96(2):365-372

PubMed: 31820435 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(7):3659-3667

PubMed: 32620605 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

BMC Complement Med Ther, 2020, 11;20(1):141

PubMed: 32393373 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Cell Rep Med, 2020, 1(9):100160

PubMed: 33377131 ( click the link to review the publication )

Theranostics, 2020, 10(5):1981-1996

PubMed: 32104496 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):663-670

PubMed: 31897182 ( click the link to review the publication )

Mol Genet Genomic Med, 2020, e1409

PubMed: 32748564 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13988

PubMed: 32814794 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:1625-1635

PubMed: 32110058 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Adv Sci (Weinh), 2019, 6(21):1900667

PubMed: 31728273 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

Biomaterials, 2019, 222:119421

PubMed: 31494503 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1004-2

PubMed: 31530934 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 14;38(1):196

PubMed: 31088567 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):600

PubMed: 31395855 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1533-1543

PubMed: 31301362 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31572672 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz032

PubMed: 31065671 ( click the link to review the publication )

Int J Mol Sci, 2019,

PubMed: 31455014 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16647

PubMed: 31719636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10845

PubMed: 31350465 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2764

PubMed: 31823522 ( click the link to review the publication )

Hum Vaccin Immunother, 2019, 10.1080/21645515.2019.1665960

PubMed: 31584324 ( click the link to review the publication )

Oncol Lett, 2019, 17(6):5023-5029

PubMed: 31186713 ( click the link to review the publication )

Oncol Lett, 2019, 5(3):935-942

PubMed: 23426424 ( click the link to review the publication )

Neoplasma, 2019, 66(1):39-45

PubMed: 30509090 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 10.1007/s13402-019-00471-x

PubMed: 31493144 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2237

PubMed: 29884866 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Cell Death Discov, 2018, 4:116

PubMed: 30588338 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2018, 356:159-171

PubMed: 30086361 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):844-854

PubMed: 29749542 ( click the link to review the publication )
Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560127 ( click the link to review the publication )

Theranostics, 2018, 8(5): 1312–1326

PubMed: 29507622 ( click the link to review the publication )

Oncotarget, 2018, 9(45):27835-27850

PubMed: 29963241 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

J Cancer, 2017, 8(17):3555-3566

PubMed: 29151941 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):15-25

PubMed: 27671335 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Cell, 2017, 170(3):548-563

PubMed: 28753429 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Cancer Lett, 2016, 380(1):87-97

PubMed: 27322737 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(11):1428-1438

PubMed: 27984028 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1772-9

PubMed: 27613096 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(10):1350-65

PubMed: 26290450 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31272-83

PubMed: 26418718 ( click the link to review the publication )

Int J Cancer, 2014, 136(4):E51-61

PubMed: 25156627 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

J Proteomics, 2014, 113:326-36

PubMed: 25451013 ( click the link to review the publication )
J Biomed Opt, 2014, 19(11):116001

PubMed: 25364948 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(12):2771-7

PubMed: 24093441 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

Optical Methods for Tumor Treatment and Detection, 2013, 10.1117/12.2010730

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[9]

Targets

DNA synthesis ^[1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)

In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. ^[1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. ^[2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Caco2	MW\GeY5kfGmxbjDBd5NigQ>?	MmeyN\|AwOTBywrFOwG0>	MoG3NVbDqGh?	MkjOSG1UVw>?	NWDrbZVt[WO2aY\heIV{KE6{ZkK=	M3LGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2	MkjFSpVv[3Srb36gRZN{[Xl?	M2\YUFMwOTBxM{Cg{txO	MkXyNVYhcA>?	M1i2dWROW09?	NF3NfFJqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCDS2KxR\|EtKE6TT{GsJGhQNTFuIF3SVFItyqCjbnTNVnA{yqCmb4PlMYRmeGWwZHXueIx6	NYLVOnlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVY1OTVpPkK0OVU3PDF3PD;hQi=>
Caco2	NWHpSWhUTnWwY4Tpc44hSXO\|YYm=	MX:zNOKh\|ryP	MoXnNlQhcA>?	NX:5fVRlTE2VTx?=	MknlbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDIU{0yNCCDS2KxR{wh[W6mIF7RU\|E>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
SW620	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHv2T\|EyOC15MDDt[{9N	NIfWenAzPC92OD:3NkBp		NXjTTGpCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NE[zNFUoRjJ2NkS2N\|A2RC:jPh?=
SW480	M2K0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1nP[lQ5KGkEoB?=		M13KdWlEPTB;MkCuPEB2\y:vTB?=	M3j5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KwOlc2Lz5{NEeyNFY4PTxxYU6=
HCT116	MUXGeY5kfGmxbjDBd5NigQ>?	MXiyM\|UhyrWP	NVnvdocyOjRxNEigbC=>		NHLvbWZ{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW\|c3nvci=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MUSxNUc,OjR5NkG0NVE9N2F-
HT-29	NHHwZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1K1UVHDqM7:TR?=	NV\iNYRoOC15MjDo		MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480	NWHIVWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnNNeKh\|ryP	NGDYeIExNTd{IHi=		NYrlfGZVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	Mk\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC	NEPYSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjvb3BKSzVyPUGxMlMxyqEEsdMgNU4xOiEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV\|MEe0OFg9N2F-
HEK293	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXNWWxKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?=	NGPGOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO\|Q1QCd-MkWzNFc1PDh:L3G+
HT-29	NVPpfJY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnOzTWM2OD53MDFOwG0>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV\|MEe0OFg9N2F-
HCT-116	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX:0d\|VvUUN3ME22MlI1yqEEsdMgNk46PyEQvF2=	NWK0V5hoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
MCF-7	NUeyc45JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUe3d3h7UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN	NU[5T5U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
HepG2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3faR2lEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?=	NF;ocnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO\|Q1QCd-MkWzNFc1PDh:L3G+
A549	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTVzLkC4xsDDucLiMUCuPVYh\|ryP	NVjlO2tCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
SGC7901	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJzLkezxsDDucLiMz6wPEDPxE1?	MkXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1	M{LZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHZTWM2OD12Nj6yNOKhyrIEoEOuNVQh\|ryP	MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HCT116	NGO0VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NkBpyqB?		NEH5V5lKSzVyPU[uNlPDuTBwN{WgxtVoN22O	MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|NkC2N\|EoRjJ3M{[wOlMyRC:jPh?=
SW480	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV23NkBpyqB?		MUfJR\|UxRTFyLkhCtVIvOjZiwsXnM41N	NGe0emQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NFY{OSd-MkWzOlA3OzF:L3G+
MIAPaCa-2	MUXGeY5kfGmxbjDBd5NigQ>?	NHrueoszPeLCidM1US=>	MkDTNlQwPDhiaB?=		M2C0dIlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG\|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg	NWf1PZNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1	M3jRe2Z2dmO2aX;uJGF{e2G7	NFjCNXMzPeLCidM1US=>	M4HDblI1NzR6IHi=		NGLEPWFqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G\|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=>	MnOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2	MVvBdI9xfG:\|aYOgRZN{[Xl?	NXTEWYdOOjYkgJpCuW0>	NHX0O\|gzPCCq		NH\yOplqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIIP5coVz\2m\|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1	M4P2TmFxd3C2b4Ppd{BCe3OjeR?=	M3W5WlI26oDLwsXN	MkX6NlQhcA>?		MV7pcoR2[2W\|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
HPDE	NI\CXWVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NInYWY0zPS93MDFOwG0>	NYXTRlVuOjRxNEigbC=>		NGm2T5FqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F?	M4G5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
SW1990	MoX4R4VtdCCYaXHibYxqfHliQYPzZZk>	MYmyOU82OCEQvF2=	Mo\5NlQwPDhiaB?=		MnfJbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2	MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHrvd\|gzPS93MDFOwG0>	MVqyOE81QCCq		Ml7GbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MlLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1	NEnxeGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NILZ[JozPS93MDFOwG0>	MWmyOE81QCCq		MoXabY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	M33ublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
A549/CDDP	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjHcoRKSzVyPUG4MlYhyrFiMT6yJO69VQ>?	NGflSYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549	M3TaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnGTWM2OD13LkigxtEhOC54IN88US=>	NYj4W3ZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR\|PD;hQi=>
SW480	M{j1UmZ2dmO2aX;uJGF{e2G7	MoXFNVDjiIoEtXevcYw>	NF\3OIczPOLCiXi=		M4jz[oVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?=	M4HyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW620	MXrGeY5kfGmxbjDBd5NigQ>?	MkDRNVDjiIoEtXevcYw>	NUf5d3pbOjUkgJno		M37yNoVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?=	NHnCR5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW480	MWXGeY5kfGmxbjDBd5NigQ>?	Mk\zNVDjiIoEtXevcYw>	NWDGfZg5OjUkgJno		MorJbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>?	NHzCdoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620	MYfGeY5kfGmxbjDBd5NigQ>?	MmLpNVDjiIoEtXevcYw>	NH;kVIYzPOLCiXi=		NE\6VFlqdmO{ZXHz[ZMhVEN\|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUSyNEc,OjV5NEm0NlA9N2F-
HT-29	NXjIW4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfy[2ZKSzVyPUWuNlIh\|ryP	NH[yOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SNU-175	NWjuflM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPmR3E5UUN3ME2xMlUyKM7:TR?=	M{TwdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
COLO-320DM	NYqyTWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTVwM{ig{txO	NXLyWopjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O\|YyPDd7PD;hQi=>
DLD-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vidmlEPTB;OD62OUDPxE1?	MmnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
DiFi	NHvxRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzReIc6UUN3ME2xNE46PSEQvF2=	NH6yW5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
HCT-15	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP1TWM2OD16Lk[0JO69VQ>?	Mnf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
SCM-1	NYW1W\|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXkZ3E5UUN3ME2xO{42KM7:TR?=	MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
TMK-1	NWnze49mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmi5TWM2OD1{Mj62JO69VQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
MKN-45	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTF2LkCg{txO	MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
AGS	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnmSHlHUUN3ME2xNE43KM7:TR?=	Mlf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
S3	NH;BOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonqTWM2OD13Mz61JOKyKDFwNTFOwG0>	NIDze3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
SiHa	NWHh[HlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjLS4hKSzVyPUCuPEDDuSByLkGg{txO	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyMUCwO{c,OjV6MEGwNFc9N2F-
HT-29	NUD4NJZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHZTWM2OD1\|NT62JO69VQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
DLD-1	M{P6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rsNGlEPTB;M{KuNkDPxE1?	M37Ye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECzNFg2Lz5{NkCwN\|A5PTxxYU6=
HT29	NYDkelI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnvTWM2OD14MzFOwG0hyrFiMUi=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNEC4OEc,OjZyMESwPFQ9N2F-
MC38	NHmzR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPIZWxiUUN3ME2yN{DPxE1iwsGgNi=>	NV\IdmpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFQxQDRpPkK2NFA1ODh2PD;hQi=>
SW620	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jKN2lEPTB;Mz62PEDPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
SW480	NYPHOWpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HYWmlEPTB;Mj64OkDPxE1?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
RKO	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTFwMkOg{txO	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
LoVo	M3TPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwMjFOwG0>	M2K3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
KM12	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjVTWM2OD12LkO3JO69VQ>?	NGDHR409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
HCT116p53-	M3LVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DMbmlEPTB;MT6wPEDPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT116	NWHNdFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXMTWM2OD1zLkC0JO69VQ>?	M1L2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
HCT15	M4Plbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nMR2lEPTB;MT60N{DPxE1?	MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
HT29	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJwNkmg{txO	NGLhXIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
DLD1	M3f2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUK3bFI2UUN3ME2yMlAyKM7:TR?=	NE\GS5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
Colo205	NFjYOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTNwM{Og{txO	M2fPUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
BE	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH64UWVKSzVyPUOuN\|Mh\|ryP	M2XQUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
CT26	MoPyR4VtdCCYaXHibYxqfHliQYPzZZk>	M2O2eFQhdU1?	NGnpbHc1QCCqwrC=		MX;k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV?	NE\w[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|AyOid-Mk[xN\|cxOTJ:L3G+
CT26	NVG1d5h3TnWwY4Tpc44hSXO\|YYm=	M3Hp[\|QhdU1?	M3v6OlQ5KGkEoB?=		Mn3NbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR\|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV?	NUnpfpFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|cxOTJpPkK2NVM4ODF{PD;hQi=>
CT26	MYfGeY5kfGmxbjDBd5NigQ>?	MnjmOEBuVQ>?	M1TXeVQ5KGkEoB?=		MoHFbY5lfWOnczDheZRweGijZ4m=	MnnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewNVIoRjJ4MUO3NFEzRC:jPh?=
SK-OV-3	MnLMSpVv[3Srb36gRZN{[Xl?	MUe1NEDPxE4EoB?=	NF\kb5M1QCCqwrC=		MkDTdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm\|aYO=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
OVCAR-5	NH3PW5pHfW6ldHnvckBCe3OjeR?=	M{DBblIxKM7:TdMg	NELFdowzPGh?		Ml;hdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm\|aYO=	M2DMb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
PA-1	Mmr5SpVv[3Srb36gRZN{[Xl?	M2DxPVExKM7:TdMg	M4nSeVI1cA>?		MlnUdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm\|aYO=	MnXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3	MWPGeY5kfGmxbjDBd5NigQ>?	MkfvOVAh\|ryP	MmXjPVYhcA>?		Mk\keZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
OVCAR-5	NV3BOG5sTnWwY4Tpc44hSXO\|YYm=	MlzrN\|Ah\|ryP	MUC0PIg>		MXv1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM>	NWrQepViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1	NFnvSWNHfW6ldHnvckBCe3OjeR?=	MnfYNVAh\|ryPwrC=	NEKzNlg1QGh?		NVfrb45YfXBvcnXneYxifGW\|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K\|	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
SK-OV-3	MlHuSpVv[3Srb36gRZN{[Xl?	NHzaXmg2OCEQvF2=	NV[1V3gxQTZiaB?=		MVf0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO=	NVvtUG9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
OVCAR-5	M1TadWZ2dmO2aX;uJGF{e2G7	MlXyN\|Ah\|ryP	MUK0PIg>		M{LVNpRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=>	NXzOOZZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1	NH;Wb2JHfW6ldHnvckBCe3OjeR?=	NUjhS4tNOTBizszNxsA>	MX[yOIg>		MUX0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
SK-OV-3	NVTvO4tyS2WubDDWbYFjcWyrdImgRZN{[Xl?	M4jKdFAuOTByIN88US=>	NEfqPIkzPC92OD:3NkBp		Ml\5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
OVCAR-5	NUP6W\|d7S2WubDDWbYFjcWyrdImgRZN{[Xl?	NHPHZmoxNTZyIN88US=>	NH3MfVAzPC92OD:3NkBp		M2rQWYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M2H2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
PA-1	NIPBdJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEfieokxNTJyIN88US=>	M3;QUFI1NzR6IHi=		MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
HCT116	NEnRV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTBwNEJCpOKyyqByLkCyJO69VQ>?	M13QSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUS4OVk3Lz5{NkG0PFU6PjxxYU6=
HT29	NWXlOpFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3We4VTUUN3ME2wMlg5yqEEsdMgNE4zKM7:TR?=	NHm0TFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG0PFU6Pid-Mk[xOFg2QTZ:L3G+
SNU-387	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;3cohKSzVyPUK1xsDDucLiMj63JO69VQ>?	NIS1fVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
SNU-475	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWmyR3pzUUN3MP-8olMxKM7:TR?=	NIrpT2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
Hep-G2	MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj2UldKSzVyPUGzMlHDqMLzwrCxMlYh\|ryP	MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
SNU-398	M1jtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zLcWlEPTB;Nj61xsDDucLiMT6xJO69VQ>?	NHTHfW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
LoVo	MmLQSpVv[3Srb36gRZN{[Xl?	NFe1fXUyNzVizszN	MWmyOE81QCCq		MkCzbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?=	NUTYZ4l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFg2OjNpPkK2NlA5PTJ\|PD;hQi=>
HCT116 p53+/+	M1rKO2Z2dmO2aX;uJGF{e2G7	M3LmblEwPSEQvF2=	NE\VXJUzPC92ODDo		NFS1dYlqdmS3Y3XzJJRz[W6\|Y4LpdJRqd26jbDDy[ZBz\XO\|aX;uJI9nKESXVD3O	MojSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEi1NlMoRjJ4MkC4OVI{RC:jPh?=
MDA-MB-231	M{S4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTGNGt1UUN3ME2yN{4yKMLzIECuNUDPxE1?	NUDOeGJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNVE2QTFpPkK2NlEyPTlzPD;hQi=>
MCF-7	M{TnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XVWmlEPTB;MUWuOEDDuSByLkOg{txO	M2r0d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
SK-BR-3	M1vQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXsN4pKSzVyPUOxMlAhyrFiMD6xJO69VQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
LoVo	NIDhZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVT0PHBlPDhiaNMg		NV3FPWp4UUN3ME25OE45OyEQvF2=	M{D0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O\|U6Lz5{NkK2PVc2QTxxYU6=
HCT116	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFjnToU1QCCqwrC=		NGH6Rm5KSzVyPUGxMlg3KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4OUe1PUc,OjZ{Nkm3OVk9N2F-
SW480	M1rtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUTYOXRmPDhiaNMg		NV3kR2pvUUN3ME2xMlg4KM7:TR?=	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O\|U6RC:jPh?=
CaES-17	MYPDfZRwfG:6aXPpeJkhSXO\|YYm=	NVXkN4ZQOOLCk{G2NOKh\|ryP	M{D4U\|Q5yqCq		M1nYPWlEPTB;NT61xsDDucLiMD6yJO69VQ>?	NVz4R4JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O\|Q3QTNpPkK2OFc1Pjl\|PD;hQi=>
HKESC-2	MVXDfZRwfG:6aXPpeJkhSXO\|YYm=	M1TlZlDjiJNzNkFCpO69VQ>?	NVrIZpp2PDkEoHi=		NXHmbY9qUUN3ME21MljDqMLzwrCwMlUh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	VEGFR-1 / NRP-1 ; PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min. p-Src(Y418) / p-FAK(Y861) ; PubMed: 19383922 Cancer Res Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	18790786 19383922
Immunofluorescence	E-cadherin / Vimentin; PubMed: 30787271 Cell Death Dis Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells. ATXN2L / G3BP1; PubMed: 30787271 Cell Death Dis Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules.	30787271
Growth inhibition assay	Cell viability ; PubMed: 28339092 Oncol Rep Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations.	28339092

In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. ^[6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. ^[7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. ^[8]

Protocol

Cell Research:

^[4]

- Collapse

Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
Concentrations: ~100 μM
Incubation Time: 48 hours
Method:
The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control

(Only for Reference)

Animal Research:

^[6]

- Collapse

Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
Dosages: 10 mg/kg
Administration: A weekly i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	3 mg/mL warmed (7.55 mM)
	Ethanol	0.01 mg/mL (0.02 mM)
	DMF	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% glucose (with warming) For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Oxaliplatin SDF

Molecular Weight	397.29
Formula	C₈H₁₄N₂O₄Pt
CAS No.	61825-94-3
Storage	2 years 4°C(in the dark) powder 1 week 4°C(in the dark) in solvent
Synonyms	L-OHP
Smiles	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04158349	Recruiting	Drug: Oxaliplatin\|Drug: mFOLFIRI	Colorectal Cancer\|Appendiceal Cancer\|Peritoneal Carcinoma	University of Utah	June 11 2020	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?
Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin (cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl (LY188011) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Bleomycin Sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin

Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.
Cytarabine

Cytarabine (Cytarabin, Ara-C, Arabinofuranosyl Cytidine) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells. Cytarabine induces autophagy and apoptosis.

Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Choose Your Country or Region

By Signaling Pathways

By product type

Oxaliplatin